Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT01514669
First received: January 17, 2012
Last updated: March 12, 2014
Last verified: March 2014
  Purpose

The purpose of this research study is to compare profiles in the blood and tears of patients with and without prostate cancer with the goal of developing a method of separating men with aggressive and non-aggressive disease.


Condition
Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer

Resource links provided by NLM:


Further study details as provided by University of Arkansas:

Biospecimen Retention:   Samples With DNA

Tear Sample collection; serum sample collection


Estimated Enrollment: 75
Study Start Date: January 2012
Groups/Cohorts
No treatment

  Eligibility

Ages Eligible for Study:   35 Years to 80 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Participants will be selected from those outpatients followed in the Winthrop P. Rockefeller Cancer Institute (located at the University of Arkansas for Medical Sciences).

Criteria

Inclusion Criteria:

  1. Male, 35-80 years old
  2. Patients who present for a routine check-up
  3. Patients who present for the evaluation of an abnormal exam or test (elevated PSA, abnormal DRE, etc.)
  4. Patients who present for the evaluation of a palpable nodule or induration on prostate exam
  5. Patients may present with a biopsy proven prostate cancer from outside physician for inclusion into arms 2 or 3
  6. For group 1 a negative prostate biopsy

Exclusion Criteria:

  1. Patient < 35 or > 81 years of age
  2. Concurrent eye infection or trauma
  3. Active conjunctivitis
  4. Abnormal production of tears (too much or too little)
  5. Any other conditions the PI or staff feels will not fulfill the criteria for study entry or will place the subject in a harmful environment
  6. Atypia on prostate biopsy report
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01514669

Locations
United States, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
Sponsors and Collaborators
University of Arkansas
Investigators
Principal Investigator: Matthew D Katz, MD University of Arkansas
  More Information

No publications provided

Responsible Party: University of Arkansas
ClinicalTrials.gov Identifier: NCT01514669     History of Changes
Other Study ID Numbers: 133719
Study First Received: January 17, 2012
Last Updated: March 12, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on July 22, 2014